Combined vandetanib–cisplatin regimen

The combined vandetanib–cisplatin regimen is a therapeutic strategy rather than a single molecular target. It involves the co-administration of vandetanib, a multi-kinase inhibitor, and cisplatin, a platinum-based chemotherapeutic agent. Vandetanib primarily targets the vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) kinase to inhibit angiogenesis and tumor cell proliferation (Source: PubChem CID 176870; FDA Label for Caprelsa). Cisplatin acts by forming DNA adducts and intra-strand cross-links, which interfere with DNA replication and transcription, ultimately triggering programmed cell death (Source: National Cancer Institute). This combination has been investigated in various clinical trials for solid tumors, such as non-small cell lung cancer and head and neck cancers, aiming to achieve synergistic anti-tumor effects by simultaneously targeting growth factor signaling pathways and inducing direct genomic damage (Source: ClinicalTrials.gov, NCT00097110). Because this entry describes a drug combination rather than a specific biological molecule or receptor, it is classified as an incorrect target designation.

Other names

Vandetanib plus cisplatinZD6474 and cisplatin combination therapyVandetanib-cisplatin doublet

Vandetanib acts as a multi-kinase inhibitor targeting VEGFR, EGFR, and RET signaling pathways, while cisplatin induces DNA cross-linking, leading to the inhibition of DNA synthesis and the induction of apoptosis.